Biocon Sdn Bhd enters Malaysia Book of Records

Biocon Sdn Bhd, Malaysia, a subsidiary of Biocon Biologics, has entered the Malaysia Book of Records, a statement from Biocon Biologics notified today.

The statement said that the 562,000 sq ft facility has been recognised as the first and largest integrated insulin manufacturer in Malaysia by MBR, which officially recognises record-creating and record-breaking achievements in the fields of human endeavour, building and structures, transportation, arts and entertainment, business, sports and games, science and technology, nature, etc in Malaysia.

Further, according to the statement, Biocon Biologics has created a Center of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins. The insulins facility in Johor is the first and only biopharma sterile injectables facility in Malaysia to receive the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) approvals.

Kiran Kumar Gandhirajan, Site Head, Malaysia, said in the statement, “………As the only insulin manufacturer in Malaysia, we have been able to achieve insulin self-sufficiency and improve insulin access while providing savings to our partner, Ministry of Health (MoH), Malaysia. Through the insulins manufactured at this facility, Biocon Biologics is also making a difference to the lives of millions of people with diabetes worldwide in line with our aspiration of taking our biosimilar insulins to ‘one-in-five’ insulin-dependent patients.”

Through Biocon Sdn Bhd, Biocon Biologics has set up Asia’s largest integrated insulin manufacturing and R&D facility in Malaysia at an investment of over $350 million. This is the largest foreign investment in biotech in Malaysia. Commercial operations at the facility commenced in 2016 when Biocon Biologics’ recombinant human insulin became the first locally manufactured biosimilar product approved for sale in Malaysia, concluded the statement.